Announcement • Jul 22
Soligenix, Inc., Annual General Meeting, Sep 17, 2026 Soligenix, Inc., Annual General Meeting, Sep 17, 2026. Announcement • Jun 13
Soligenix, Inc. Receives Notice of Non-Compliance with Nasdaq Listing Rule 5550(A)(2) Minimum Bid Price Requirement On June 10, 2026, Soligenix, Inc. (the Company) received a written notice (the Bid Price Notice) from the Listing Qualifications department (the Nasdaq Staff) of The Nasdaq Stock Market (Nasdaq) indicating that the Company is not in compliance with the $1.00 minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market. The notification of noncompliance has no immediate effect on the listing or trading of the Company's common stock on The Nasdaq Capital Market under the symbol SNGX, and the Company is currently monitoring the closing bid price of its common stock and evaluating its alternatives, if appropriate, to resolve the deficiency and regain compliance with this rule. The Nasdaq Listing Rules require listed securities to maintain a minimum bid price of $1.00 per share and, based upon the closing bid price for the last 30 consecutive business days, the Company no longer meets this requirement. The Bid Price Notice indicated that the Company will be provided 180 calendar days, or until December 7, 2026, in which to regain compliance. If at any time during this period the bid price of the Company's common stock closes at or above $1.00 per share for a minimum of ten consecutive business days, the Nasdaq Staff will provide the Company with a written confirmation of compliance and the matter will be closed. In the event the Company does not regain compliance with Rule 5550(a)(2) prior to the expiration of the 180 calendar day period, the Nasdaq Staff will provide the Company with written notification that its securities are subject to delisting from The Nasdaq Capital Market. At that time, the Company may appeal the delisting determination to a Nasdaq Listing Qualifications Panel. Alternatively, if the Company fails to regain compliance with Rule 5550(a)(2) prior to the expiration of the 180 calendar day period, but meets the continued listing requirement for market value of publicly held shares and all of the other applicable standards for initial listing on The Nasdaq Capital Market, with the exception of the minimum bid price, and provides written notice of its intention to cure the deficiency during the second compliance period by effecting a reverse stock split, if necessary, then the Company may be granted an additional 180 calendar days to regain compliance with Rule 5550(a)(2). Announcement • Jun 09
Soligenix Applies for Vaccine Development Funding for Bundibugyo Ebola Vaccine Soligenix announced in collaboration with Axel Lehrer, PhD, Professor in the Department of Tropical Medicine, Medical Microbiology and Pharmacology at the John A. Burns School of Medicine, University of Hawai?i at Manoa, has previously developed bivalent and trivalent thermostable vaccines, constructed from antigens against Ebola virus, Sudan virus and Marburg virus and the CoVaccine HT™ adjuvant, demonstrating thermostability, immunogenicity and durable efficacy in non-human primates. This work, combined with previous and ongoing work in Dr. Lehrer's laboratory that has demonstrated platform compatibility of the key Bundibugyo virus antigen, will form the basis of an application to CEPI enabling rapid development of a protein-based thermostable subunit vaccine for BDBV. The proprietary platform encompasses a suite of highly efficacious subunit protein vaccines formulated using recombinantly expressed Orthoebolavirussudanense glycoprotein, Orthoebolavirus zairense glycoprotein and Orthomarburgvirusmarburgense glycoprotein developed in partnership with Dr. Axel Lehrer at the University of Hawai?i at Manoa. Dr. Lehrer's team has also previously used the same expression platform to produce glycoprotein of Orthoebolavirus bundibugyoense, which has already found application in collaborative seroepidemiology studies conducted in the Democratic Republic of the Congo (DRC). All filovirus vaccines include a protein found on the surface of each virus, to engender an appropriate immune response without posing a risk of infection, as well as a novel adjuvant which stimulates both humoral and cell mediated immune responses, in combination with Generally Regarded As Safe (GRAS) excipients that enable lyophilization (i.e., freeze-drying) of the vaccines. The resulting products are manufactured as a heat stable powder in a vial which is reconstituted with widely available water for injection immediately prior to use. Alone or in combination, these heat stable protein subunit vaccines, have protected up to100% of non-human primates exposed to a lethal injection of the corresponding virus. Stability studies have demonstrated that these vaccines are heat stable for at least 2 years at temperatures of at least 40 degrees Celsius (104 degrees Fahrenheit). Manufacture of the recombinant proteins utilizes a robust protein manufacturing process, developed and tested in other subunit vaccines advanced through clinical testing. Similarly, the selected adjuvant, while novel, has also been independently tested in Phase 1 and Phase 2 clinical studies. Soligenix has been granted Orphan Drug Designation by the United States Food and Drug Administration (FDA) for the prevention and post-exposure prophylaxis against Orthoebolavirussudanense and Orthomarburgvirusmarburgense infection. In addition to providing a seven-year term of market exclusivity upon final FDA approval, orphan drug designations also position Soligenix to be able to leverage a wide range of financial and regulatory benefits, including government grants for conducting clinical trials, waiver of expensive FDA user fees for the potential submission of a Biologics License Application (BLA), and certain tax credits. There currently are limited treatment options for Ebola Virus Disease and no available treatments for Sudan, Bundibugyo or Marburg Virus Disease, although steady progress has also been made in development of immunotherapeutics for filoviruses beyond Orthoebolavirus zairense. There are approved vaccines for Ebola virus, requiring stringent ultra-low cold-chain storage, but no efficacious and approved vaccines are available for Sudan, Bundibugyo, or Marburg virus. 
